Tertiary Nav - Press Releases Press ReleasesMedia Statements Press Releases Items Per Page 102550 News Category Business & FinancialCitizenshipEarningsMedia StatementProduct NewsRecognitionRegulatoryScience & Innovation Year None202320222021202020192018201720162015201420132012201120102009200820072006 Date Title 10/12/21 Sarepta Therapeutics Announces Preliminary Financial Results for the Third Quarter Ended September 30, 2021 10/12/21 Sarepta Therapeutics Announces Proposed $500,000,000 Public Offering of Common Stock 10/11/21 Sarepta Therapeutics’ SRP-9001 Shows Sustained Functional Improvements in Multiple Studies of Patients with Duchenne 10/4/21 Sarepta Therapeutics Opens Genetic Therapies Center of Excellence in Columbus, Ohio 10/4/21 Sarepta Therapeutics Announces Initiation of EMBARK, a Global Pivotal Study of SRP-9001, a Gene Therapy for the Treatment of Duchenne Muscular Dystrophy 9/30/21 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 9/27/21 Sarepta Therapeutics to Initiate Part B of MOMENTUM Study of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping Following Positive Interactions with FDA 9/14/21 Sarepta Therapeutics to Showcase Data from its Gene Therapy and RNA Platforms at World Muscle Society 2021 Virtual Congress 9/7/21 Sarepta Therapeutics to Present at Upcoming Investor Conferences 9/7/21 Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program Pagination First page « first Previous page ‹ previous … Page 4 Page 5 Page 6 Page 7 Current page 8 Page 9 Page 10 Page 11 Page 12 … Next page next › Last page last » Displaying 71 - 80 of 768 Toolkit Print Page | Email Alerts | RSS Feeds | Contacts
Press Releases Items Per Page 102550 News Category Business & FinancialCitizenshipEarningsMedia StatementProduct NewsRecognitionRegulatoryScience & Innovation Year None202320222021202020192018201720162015201420132012201120102009200820072006 Date Title 10/12/21 Sarepta Therapeutics Announces Preliminary Financial Results for the Third Quarter Ended September 30, 2021 10/12/21 Sarepta Therapeutics Announces Proposed $500,000,000 Public Offering of Common Stock 10/11/21 Sarepta Therapeutics’ SRP-9001 Shows Sustained Functional Improvements in Multiple Studies of Patients with Duchenne 10/4/21 Sarepta Therapeutics Opens Genetic Therapies Center of Excellence in Columbus, Ohio 10/4/21 Sarepta Therapeutics Announces Initiation of EMBARK, a Global Pivotal Study of SRP-9001, a Gene Therapy for the Treatment of Duchenne Muscular Dystrophy 9/30/21 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 9/27/21 Sarepta Therapeutics to Initiate Part B of MOMENTUM Study of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping Following Positive Interactions with FDA 9/14/21 Sarepta Therapeutics to Showcase Data from its Gene Therapy and RNA Platforms at World Muscle Society 2021 Virtual Congress 9/7/21 Sarepta Therapeutics to Present at Upcoming Investor Conferences 9/7/21 Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program Pagination First page « first Previous page ‹ previous … Page 4 Page 5 Page 6 Page 7 Current page 8 Page 9 Page 10 Page 11 Page 12 … Next page next › Last page last » Displaying 71 - 80 of 768